Kevin Pojasek
@drkpoj
ceo / venture partner / company builder / kendall sq expat
You might like
Are you a leader in cell therapy research looking for a new adventure? Please join us for the next phase of our journey! @Enara_Bio
We are growing our team at #EnaraBio! We are excited to share the newly created role of Vice President of Cell Therapy Research. Please follow enarabio.com/careers/vice-p… to learn more and apply #Careers
We are rebranding as Enara Bio to reflect a broader emphasis on the discovery and development of novel #TCR based cancer #immunotherapies bit.ly/3dvPb38
The beginning ends Ervaxx lives in Enara We light the voyage lnkd.in/dUi2r5E
Thrilled today to announce our collaboration with @cardiffuni to develop novel #Tcell and #TCR immunotheraies targeting #DarkAntigens. We will also build on exciting new research in @NatImmunol identifying #MR1 as a target for novel #immunotherapy. bit.ly/2NRXifB
Come work with us! We are looking for a Scientist/Senior Scientist to join our growing immunology team and help develop #darkantigens for #cancer #immunotherapy. See our website for more info and to apply: bit.ly/307g5Zq
Congrats, Arkuda team! Looking forward to hearing news of future progress.
Armed with $44 million from the likes of Atlas Venture and Pfizer Ventures, the Cambridge, Massachusetts-based biotech is going after progranulin, a protein that plays a role in neuronal health and the function of lysosomes: fiercebiotech.com/biotech/arkuda…
We're excited to be presenting our first data at the @sitcancer annual meeting on Nov 9: ‘Discovery of immunogenic ERV-derived antigens as targets for melanoma immunotherapy.’ bit.ly/2JV2hKG #DarkAntigens #cancervaccines #immunotherapy #melanoma
Thrilled to formally unveil our Dark Antigen discovery efforts @ErvaxxLtd today! Fascinating area of emerging biology - non-canonical ORFs generating shared tumor-specific T-cell antigens.
Congrats, gents! Impressive next step for team Atlas.
We are excited to announce the first Atlas Venture Opportunity Fund, building upon our venture creation model with growth investments in high-potential Atlas portfolio companies. Learn more here: businesswire.com/news/home/2019…
And a great CEO! What’s not to love!? Congrats, Jeff.
Thrilled to be part of the @ambysmedicines team! Terrific colleagues, bold science, amazing founders, top investors, great partnership, three platforms (traditional, gene and cell therapy approaches) and planning to make liver transplants obsolete. This is going to be fun!
The Immunocore Autoimmune team representing at @KeystoneSymp conference - Frontiers in Islet Biology & Diabetes. Their first poster at an international conference - great job guys!
Immunocore is so proud of our employee Alex Powlesland -the UK's most prolific inventor - Read about his achievements in an @Oxfordtimes article here bit.ly/2DNqcYa
I’m excited about the possibilities that exist at the intersection of global health and the private sector. I spoke about how companies can harness these opportunities earlier today. b-gat.es/2CTjwuf
Quartet was a great team all the way around - internal team, investors, founders, SAB. But science happens. At it again already though . . .
Painful Truth: Successful Failure Of A Biotech Startup. An investor's eulogy for @QuartetMed. lifescivc.com/2017/11/painfu… @MJT_262385 @drkpoj
Congrats #DDF - what a great partner in tackling dementia! Patients and their families are waiting with baited breath!
Biology, biomarkers, novel mechanisms, registries, and data sharing. All reasonable even though details sparse. endpts.com/bill-gates-has…
endpoints.news
Bill Gates has a $100M and a 5-point strategy to end 15 years of failure in Alzheimer’s R&D
Bill Gates is going after Alzheimer’s. The software billionaire is investing $50 million of his own money — not from the Gates Foundation — into the industry/government backed Dementia Discovery...
Is that the inimitable @MikeDybbs front and center at our SITC poster!?
Immunocore presents promising overall survival data with #IMCgp100 in #Uveal #Melanoma. Thanks to Dr. Omid Hamid @OmidHamidMD for presenting at SITC. #SITC2017
Our opportunity as an AI & computing company addressing pharma's needs is "fossilization" of old technologies - ripe for disruption. Andrew Hopkins, CEO of @exscientialtd #FTPharma
Great to see @immunocore in Europe's Top 10 most innovative HIV treatments!
New Infographic: The 10 Most #Innovative #HIV #Treatments to Defeat #AIDS. @ABIVAX_ @ViiVHC @Immunocore goo.gl/PCpBsE
Reminded of @Bicycle_tx Ros Deegan's excellent post after an 'awesome-filled' day in the @Immunocore US office - lifescivc.com/2017/08/crossi…
lifescivc.com
Crossing The Sea: Adventures In Transatlantic Biotech Operations - LifeSciVC
This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. On my first morning as a US-based employee, I took advantage of the hotel’s...
United States Trends
- 1. Marshawn Kneeland 13.1K posts
- 2. Nancy Pelosi 18.1K posts
- 3. #MichaelMovie 24.9K posts
- 4. ESPN Bet 2,013 posts
- 5. #NO1ShinesLikeHongjoong 19.5K posts
- 6. #영원한_넘버원캡틴쭝_생일 19.3K posts
- 7. Gremlins 3 2,185 posts
- 8. Good Thursday 34.4K posts
- 9. Jaafar 7,454 posts
- 10. Madam Speaker N/A
- 11. Joe Dante N/A
- 12. #thursdayvibes 2,761 posts
- 13. Mega Chimecho 3,488 posts
- 14. Happy Friday Eve N/A
- 15. #BrightStar_THE8Day 29.1K posts
- 16. Penn 9,135 posts
- 17. Baxcalibur 2,932 posts
- 18. Chris Columbus 1,984 posts
- 19. Korrina 3,179 posts
- 20. Votar No 27.2K posts
You might like
Something went wrong.
Something went wrong.